FDA warned B4B Corp. that its Earth Tea Extra Strength is an unapproved, misbranded drug promoted to treat or prevent COVID-19.
What happened
FDA and FTC reviewed B4B Corp.'s website on January 25, 2021 and January 29, 2021, respectively, and also reviewed its Twitter page. FDA found Earth Tea Extra Strength offered for sale with claims that it can mitigate, prevent, treat, diagnose, or cure COVID-19. The letter says the product is an unapproved new drug and a misbranded drug.
What FDA found
Earth Tea Extra Strength is an unapproved new drug because it is offered with claims to mitigate, prevent, treat, diagnose, or cure COVID-19 without FDA approval.
Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The product is misbranded because its labeling and website claims present it as safe or effective for COVID-19 when it is not approved for that use.
Section 502 of the FD&C Act, 21 U.S.C. § 352The company introduced or delivered the product into interstate commerce even though it is unapproved and misbranded.
Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)Website and Twitter posts claimed Earth Tea works fast to eliminate quarantine, stops COVID-19 coughing 100%, fights SARS-CoV-2, and gets users back to normal in 24-48 hours.
The company advertised that Earth Tea Extra Strength can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence, including well-controlled human studies.
FTC Act, 15 U.S.C. 41 et seq.
What FDA wants
FDA tells the company to immediately stop selling unapproved products claimed to treat or prevent COVID-19 and, within 48 hours, email the COVID-19 task force with the steps taken, how it will prevent recurrence, and supporting documents.
Who should pay attention
- online sellers of tea and supplements that make disease claims
- marketing and social media teams posting health claims
- retailers and platforms that list COVID-19 treatment products
This is a summary. Read the original letter on fda.gov.